Point-of-Care Influenza Diagnostics Market Size, Share and Growth Outlook 2026: By Type (Molecular Diagnostic Tests, Traditional Diagnostic Tests), By Technology, By End User, Companies to 2034.
The global Point-of-Care Influenza Diagnostics Market size is forecast to increase from $497.21 Million in 2026 to $824.12 Million in 2034 at a CAGR of 6.52% between 2026 and 2034.
The Point-of-Care Influenza Diagnostics market report provides detailed analysis and outlook of Point-of-Care Influenza Diagnostics segments including By Type (Molecular Diagnostic Tests, Traditional Diagnostic Tests), By Technology (Nucleic Acid Amplification Tests, Lateral Flow Assay, Immunofluorescence Assays, Others), By End User (Hospitals/Clinical Laboratories, Reference Laboratories, Other End Users) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Point-of-Care Influenza Diagnostics Industry Overview
Rapid Respiratory Testing and Global Surveillance Integration Are Driving Innovation in Influenza Diagnostics
The Point-of-Care (POC) Influenza Diagnostics industry continues to evolve as healthcare systems prioritize rapid diagnosis, decentralized testing, and real-time surveillance capabilities to improve the management of seasonal and emerging respiratory infections. Growing demand for immediate clinical decision-making, antimicrobial stewardship, and outbreak preparedness is accelerating the adoption of point-of-care diagnostic platforms across hospitals, physician offices, pharmacies, urgent care centers, and community healthcare settings. Advances in molecular diagnostics, multiplex respiratory panels, and portable testing technologies are enabling faster and more accurate identification of influenza viruses while supporting broader public health surveillance objectives. The industry is increasingly characterized by the close integration of diagnostic development with global epidemiological monitoring systems and pandemic preparedness initiatives.
Global Surveillance Programs Continue to Shape Diagnostic Development Strategies
One of the most important factors influencing the point-of-care influenza diagnostics market is the continuous evolution of influenza viruses and the corresponding need for diagnostic platforms to maintain alignment with circulating strains. Regulatory agencies, public health organizations, and diagnostic manufacturers rely heavily on global surveillance networks to ensure testing accuracy and clinical relevance. Reflecting this dynamic, the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee conducted its annual review of global influenza surveillance data and recommended a trivalent vaccine composition targeting H1N1, H3N2, and Victoria lineage influenza B viruses for the upcoming influenza season. These surveillance-driven decisions play a critical role in guiding diagnostic manufacturers as they update and validate point-of-care testing platforms to ensure accurate detection of current and anticipated viral variants.
Pandemic Preparedness and Decentralized Testing Are Expanding the Strategic Role of POC Diagnostics
The growing emphasis on pandemic preparedness and coordinated global disease surveillance is reinforcing the importance of rapid point-of-care testing as a frontline public health tool. Clinical guidance and international policy initiatives increasingly recognize that early detection and decentralized testing capabilities are essential for effective outbreak management and patient care. The Centers for Disease Control and Prevention's seasonal influenza guidance continues to emphasize the importance of rapid testing and ongoing surveillance as primary strategies for managing influenza-like illnesses and seasonal disease surges. Simultaneously, the World Health Organization's efforts to finalize the Pandemic Agreement and the associated Pathogen Access and Benefit Sharing framework aim to strengthen international pathogen surveillance, data sharing, and emergency response coordination. These initiatives are expected to accelerate the development and deployment of next-generation point-of-care influenza diagnostic platforms capable of rapidly identifying both seasonal and emerging respiratory pathogens across diverse healthcare environments.
Point-of-Care Influenza Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Point-of-Care Influenza Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., bioM?rieux SA (BioFire), QIAGEN N.V., Hologic, Inc., Bio-Rad Laboratories, Inc.. The Point-of-Care Influenza Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Point-of-Care Influenza Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Point-of-Care Influenza Diagnostics industry include- Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., bioM?rieux SA (BioFire), QIAGEN N.V., Hologic, Inc., Bio-Rad Laboratories, Inc.. The Point-of-Care Influenza Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Point-of-Care Influenza Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Point-of-Care Influenza Diagnostics market remains one of the strongest-performing segments in the country.
The US Point-of-Care Influenza Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Point-of-Care Influenza Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Point-of-Care Influenza Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Point-of-Care Influenza Diagnostics markets
Canada's strong Point-of-Care Influenza Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Point-of-Care Influenza Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Point-of-Care Influenza Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Point-of-Care Influenza Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Point-of-Care Influenza Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Point-of-Care Influenza Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Point-of-Care Influenza Diagnostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Point-of-Care Influenza Diagnostics sales through 2034
France Point-of-Care Influenza Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Point-of-Care Influenza Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Point-of-Care Influenza Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Point-of-Care Influenza Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Point-of-Care Influenza Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Point-of-Care Influenza Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Point-of-Care Influenza Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Point-of-Care Influenza Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Point-of-Care Influenza Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Point-of-Care Influenza Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Point-of-Care Influenza Diagnostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Point-of-Care Influenza Diagnostics Market Segmentation
By Type
Molecular Diagnostic Tests
Traditional Diagnostic Tests
By Technology
Nucleic Acid Amplification Tests
Lateral Flow Assay
Immunofluorescence Assays
Others
By End User
Hospitals/Clinical Laboratories
Reference Laboratories
Other End Users
Leading Companies in Point-of-Care Influenza Diagnostics Industry (2026)
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche Ltd
QuidelOrtho Corporation
Thermo Fisher Scientific Inc.
bioM?rieux SA (BioFire)
QIAGEN N.V.
Hologic, Inc.
Bio-Rad Laboratories, Inc.
Countries Included
The Point-of-Care Influenza Diagnostics market report provides detailed analysis and outlook of Point-of-Care Influenza Diagnostics segments including By Type (Molecular Diagnostic Tests, Traditional Diagnostic Tests), By Technology (Nucleic Acid Amplification Tests, Lateral Flow Assay, Immunofluorescence Assays, Others), By End User (Hospitals/Clinical Laboratories, Reference Laboratories, Other End Users) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Point-of-Care Influenza Diagnostics Industry Overview
Rapid Respiratory Testing and Global Surveillance Integration Are Driving Innovation in Influenza Diagnostics
The Point-of-Care (POC) Influenza Diagnostics industry continues to evolve as healthcare systems prioritize rapid diagnosis, decentralized testing, and real-time surveillance capabilities to improve the management of seasonal and emerging respiratory infections. Growing demand for immediate clinical decision-making, antimicrobial stewardship, and outbreak preparedness is accelerating the adoption of point-of-care diagnostic platforms across hospitals, physician offices, pharmacies, urgent care centers, and community healthcare settings. Advances in molecular diagnostics, multiplex respiratory panels, and portable testing technologies are enabling faster and more accurate identification of influenza viruses while supporting broader public health surveillance objectives. The industry is increasingly characterized by the close integration of diagnostic development with global epidemiological monitoring systems and pandemic preparedness initiatives.
Global Surveillance Programs Continue to Shape Diagnostic Development Strategies
One of the most important factors influencing the point-of-care influenza diagnostics market is the continuous evolution of influenza viruses and the corresponding need for diagnostic platforms to maintain alignment with circulating strains. Regulatory agencies, public health organizations, and diagnostic manufacturers rely heavily on global surveillance networks to ensure testing accuracy and clinical relevance. Reflecting this dynamic, the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee conducted its annual review of global influenza surveillance data and recommended a trivalent vaccine composition targeting H1N1, H3N2, and Victoria lineage influenza B viruses for the upcoming influenza season. These surveillance-driven decisions play a critical role in guiding diagnostic manufacturers as they update and validate point-of-care testing platforms to ensure accurate detection of current and anticipated viral variants.
Pandemic Preparedness and Decentralized Testing Are Expanding the Strategic Role of POC Diagnostics
The growing emphasis on pandemic preparedness and coordinated global disease surveillance is reinforcing the importance of rapid point-of-care testing as a frontline public health tool. Clinical guidance and international policy initiatives increasingly recognize that early detection and decentralized testing capabilities are essential for effective outbreak management and patient care. The Centers for Disease Control and Prevention's seasonal influenza guidance continues to emphasize the importance of rapid testing and ongoing surveillance as primary strategies for managing influenza-like illnesses and seasonal disease surges. Simultaneously, the World Health Organization's efforts to finalize the Pandemic Agreement and the associated Pathogen Access and Benefit Sharing framework aim to strengthen international pathogen surveillance, data sharing, and emergency response coordination. These initiatives are expected to accelerate the development and deployment of next-generation point-of-care influenza diagnostic platforms capable of rapidly identifying both seasonal and emerging respiratory pathogens across diverse healthcare environments.
Point-of-Care Influenza Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Point-of-Care Influenza Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., bioM?rieux SA (BioFire), QIAGEN N.V., Hologic, Inc., Bio-Rad Laboratories, Inc.. The Point-of-Care Influenza Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Point-of-Care Influenza Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Point-of-Care Influenza Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Point-of-Care Influenza Diagnostics companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Point-of-Care Influenza Diagnostics markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Point-of-Care Influenza Diagnostics industry include- Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., bioM?rieux SA (BioFire), QIAGEN N.V., Hologic, Inc., Bio-Rad Laboratories, Inc.. The Point-of-Care Influenza Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Point-of-Care Influenza Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Point-of-Care Influenza Diagnostics market remains one of the strongest-performing segments in the country.
The US Point-of-Care Influenza Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Point-of-Care Influenza Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Point-of-Care Influenza Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Point-of-Care Influenza Diagnostics markets
Canada's strong Point-of-Care Influenza Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Point-of-Care Influenza Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Point-of-Care Influenza Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Point-of-Care Influenza Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Point-of-Care Influenza Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Point-of-Care Influenza Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Point-of-Care Influenza Diagnostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Point-of-Care Influenza Diagnostics sales through 2034
France Point-of-Care Influenza Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Point-of-Care Influenza Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Point-of-Care Influenza Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Point-of-Care Influenza Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Point-of-Care Influenza Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Point-of-Care Influenza Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Point-of-Care Influenza Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Point-of-Care Influenza Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Point-of-Care Influenza Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Point-of-Care Influenza Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Point-of-Care Influenza Diagnostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Point-of-Care Influenza Diagnostics Market Segmentation
By Type
Molecular Diagnostic Tests
Traditional Diagnostic Tests
By Technology
Nucleic Acid Amplification Tests
Lateral Flow Assay
Immunofluorescence Assays
Others
By End User
Hospitals/Clinical Laboratories
Reference Laboratories
Other End Users
Leading Companies in Point-of-Care Influenza Diagnostics Industry (2026)
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche Ltd
QuidelOrtho Corporation
Thermo Fisher Scientific Inc.
bioM?rieux SA (BioFire)
QIAGEN N.V.
Hologic, Inc.
Bio-Rad Laboratories, Inc.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Point-of-Care Influenza Diagnostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Point-of-Care Influenza Diagnostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Point-of-Care Influenza Diagnostics Markets in 2026
3.2. Global Historic and Forecast Point-of-Care Influenza Diagnostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Point-of-Care Influenza Diagnostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Point-of-Care Influenza Diagnostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Point-of-Care Influenza Diagnostics Value Chain
CHAPTER 4- POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Point-of-Care Influenza Diagnostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Type
Molecular Diagnostic Tests
Traditional Diagnostic Tests
By Technology
Nucleic Acid Amplification Tests
Lateral Flow Assay
Immunofluorescence Assays
Others
By End User
Hospitals/Clinical Laboratories
Reference Laboratories
Other End Users
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Point-of-Care Influenza Diagnostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
7.5. North America Point-of-Care Influenza Diagnostics Market Size Outlook by Type
7.6. North America Point-of-Care Influenza Diagnostics Market Size Outlook by Application
7.7. North America Point-of-Care Influenza Diagnostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Point-of-Care Influenza Diagnostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Point-of-Care Influenza Diagnostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Point-of-Care Influenza Diagnostics Companies
CHAPTER 8- EUROPE POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Point-of-Care Influenza Diagnostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
8.5. Europe Point-of-Care Influenza Diagnostics Market Size Outlook by Type
8.6. Europe Point-of-Care Influenza Diagnostics Market Size Outlook by Application
8.7. Europe Point-of-Care Influenza Diagnostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Point-of-Care Influenza Diagnostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Point-of-Care Influenza Diagnostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Point-of-Care Influenza Diagnostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Point-of-Care Influenza Diagnostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Point-of-Care Influenza Diagnostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Point-of-Care Influenza Diagnostics Companies
CHAPTER 9- ASIA PACIFIC POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Point-of-Care Influenza Diagnostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Point-of-Care Influenza Diagnostics Market Size Outlook by Type
9.6. Asia Pacific Point-of-Care Influenza Diagnostics Market Size Outlook by Application
9.7. Asia Pacific Point-of-Care Influenza Diagnostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Point-of-Care Influenza Diagnostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Point-of-Care Influenza Diagnostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Point-of-Care Influenza Diagnostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Point-of-Care Influenza Diagnostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Point-of-Care Influenza Diagnostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Point-of-Care Influenza Diagnostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Point-of-Care Influenza Diagnostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Point-of-Care Influenza Diagnostics Market Size Outlook by Type
10.6. South and Central America Point-of-Care Influenza Diagnostics Market Size Outlook by Application
10.7. South and Central America Point-of-Care Influenza Diagnostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Point-of-Care Influenza Diagnostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Point-of-Care Influenza Diagnostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Point-of-Care Influenza Diagnostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Point-of-Care Influenza Diagnostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Point-of-Care Influenza Diagnostics Market Size Outlook by Type
11.6. Middle East and Africa Point-of-Care Influenza Diagnostics Market Size Outlook by Application
11.7. Middle East and Africa Point-of-Care Influenza Diagnostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Point-of-Care Influenza Diagnostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Point-of-Care Influenza Diagnostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Point-of-Care Influenza Diagnostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Point-of-Care Influenza Diagnostics Industry
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche Ltd
QuidelOrtho Corporation
Thermo Fisher Scientific Inc.
bioM?rieux SA (BioFire)
QIAGEN N.V.
Hologic, Inc.
Bio-Rad Laboratories, Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Point-of-Care Influenza Diagnostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Point-of-Care Influenza Diagnostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Point-of-Care Influenza Diagnostics Markets in 2026
3.2. Global Historic and Forecast Point-of-Care Influenza Diagnostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Point-of-Care Influenza Diagnostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Point-of-Care Influenza Diagnostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Point-of-Care Influenza Diagnostics Value Chain
CHAPTER 4- POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Point-of-Care Influenza Diagnostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Type
Molecular Diagnostic Tests
Traditional Diagnostic Tests
By Technology
Nucleic Acid Amplification Tests
Lateral Flow Assay
Immunofluorescence Assays
Others
By End User
Hospitals/Clinical Laboratories
Reference Laboratories
Other End Users
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Point-of-Care Influenza Diagnostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
7.5. North America Point-of-Care Influenza Diagnostics Market Size Outlook by Type
7.6. North America Point-of-Care Influenza Diagnostics Market Size Outlook by Application
7.7. North America Point-of-Care Influenza Diagnostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Point-of-Care Influenza Diagnostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Point-of-Care Influenza Diagnostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Point-of-Care Influenza Diagnostics Companies
CHAPTER 8- EUROPE POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Point-of-Care Influenza Diagnostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
8.5. Europe Point-of-Care Influenza Diagnostics Market Size Outlook by Type
8.6. Europe Point-of-Care Influenza Diagnostics Market Size Outlook by Application
8.7. Europe Point-of-Care Influenza Diagnostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Point-of-Care Influenza Diagnostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Point-of-Care Influenza Diagnostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Point-of-Care Influenza Diagnostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Point-of-Care Influenza Diagnostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Point-of-Care Influenza Diagnostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Point-of-Care Influenza Diagnostics Companies
CHAPTER 9- ASIA PACIFIC POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Point-of-Care Influenza Diagnostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Point-of-Care Influenza Diagnostics Market Size Outlook by Type
9.6. Asia Pacific Point-of-Care Influenza Diagnostics Market Size Outlook by Application
9.7. Asia Pacific Point-of-Care Influenza Diagnostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Point-of-Care Influenza Diagnostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Point-of-Care Influenza Diagnostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Point-of-Care Influenza Diagnostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Point-of-Care Influenza Diagnostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Point-of-Care Influenza Diagnostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Point-of-Care Influenza Diagnostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Point-of-Care Influenza Diagnostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Point-of-Care Influenza Diagnostics Market Size Outlook by Type
10.6. South and Central America Point-of-Care Influenza Diagnostics Market Size Outlook by Application
10.7. South and Central America Point-of-Care Influenza Diagnostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Point-of-Care Influenza Diagnostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Point-of-Care Influenza Diagnostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Point-of-Care Influenza Diagnostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA POINT-OF-CARE INFLUENZA DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Point-of-Care Influenza Diagnostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Point-of-Care Influenza Diagnostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Point-of-Care Influenza Diagnostics Market Size Outlook by Type
11.6. Middle East and Africa Point-of-Care Influenza Diagnostics Market Size Outlook by Application
11.7. Middle East and Africa Point-of-Care Influenza Diagnostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Point-of-Care Influenza Diagnostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Point-of-Care Influenza Diagnostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Point-of-Care Influenza Diagnostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Point-of-Care Influenza Diagnostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Point-of-Care Influenza Diagnostics Industry
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche Ltd
QuidelOrtho Corporation
Thermo Fisher Scientific Inc.
bioM?rieux SA (BioFire)
QIAGEN N.V.
Hologic, Inc.
Bio-Rad Laboratories, Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
